Status:
TERMINATED
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Lead Sponsor:
Pfizer
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.
Detailed Description
The trial was terminated prematurely June 26, 2005 due to the inability to re-supply study drug for the planned number of subjects. There were no safety or efficacy concerns regarding the study in the...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson Disease
- Must be experiencing sleep akinesia
Exclusion
- Current treatment with other dopamine agonists
- Nocturnal hallucinations
- Dementia
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00174239
Start Date
July 1 2004
End Date
September 1 2005
Last Update
May 25 2007
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Westmead, New South Wales, Australia
2
Pfizer Investigational Site
Brisbane, Queensland, Australia
3
Pfizer Investigational Site
Loc. Camerelle - Pozzilli, IS, Italy
4
Pfizer Investigational Site
Vittoria, Ragusa, Italy